Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors

US9555033B2 · kind B2 · utility

Assignee

• Signal Pharmaceuticals, LLC · US

Inventors

• Rajesh Chopra · San Ramon, US
• Yuhong Ning · San Diego, US
• Sabita Sankar · San Diego, US
• Shuichan Xu · San Diego, US
• Weiming Xu · Hangzhou City, CN

Key dates

• Filing date: Feb 3, 2011
• Grant date: Jan 31, 2017
• Expiry date: Mar 7, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.